Protein detail
CD3G
T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g)
Entry name CD3G | UniProt ID | EVMP confidence score 0.50 |
Supporting publications (n) 2 | Transmembrane count 1 | Protein classification CD markersDisease related genesFDA approved drug targetsHuman disease related genesPlasma proteinsPredicted intracellular proteinsPredicted membrane proteins |
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40Basic Information13
Protein Names
T-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g)
Protein Class (7)
CD markersDisease related genesFDA approved drug targetsHuman disease related genesPlasma proteinsPredicted intracellular proteinsPredicted membrane proteins
Protein Function (5)
- Predicted intracellular proteins
- CD markers
- Human disease related genes:Immune system diseases:Primary immunodeficiency
- Disease related genes
- FDA approved drug targets:Biotech drugs
Transmembrane
117..137; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Synonym (2)
CD3-GAMMACD3GAMMA
Gene Description
CD3 gamma subunit of T-cell receptor complex
Chromosome
11
Position
118344344-118355161
Supporting publications (n)
2
EVMP confidence score
0.50
Fluorescence & Localization4
Tissue Specificheart muscleCell SpecificCardiomyocytesSingle-Nuclei Brain Specificependymal cell
Function & Pathway7
Protein Function (5)
- Predicted intracellular proteins
- CD markers
- Human disease related genes:Immune system diseases:Primary immunodeficiency
- Disease related genes
- FDA approved drug targets:Biotech drugs
Cellular Component (6)
Molecular Function (5)
Biological Process (3)
KEGG (10)
- hsa04640 Hematopoietic cell lineage
- KEGG:hsa04658 Th1 and Th2 cell differentiation
- KEGG:hsa04659 Th17 cell differentiation
- KEGG:hsa04660 T cell receptor signaling pathway
- KEGG:hsa05142 Chagas disease
- KEGG:hsa05162 Measles
- KEGG:hsa05166 Human T-cell leukemia virus 1 infection
- KEGG:hsa05169 Epstein-Barr virus infection
- KEGG:hsa05170 Human immunodeficiency virus 1 infection
- KEGG:hsa05235 PD-L1 expression and PD-1 checkpoint pathway in cancer
Reactome (21)
- R-hsa-1280218 adaptive immune system
- R-hsa-9662851 anti inflammatory response favouring leishmania parasite infection
- R-hsa-8856825 cargo recognition for clathrin mediated endocytosis
- R-hsa-8856828 clathrin mediated endocytosis
- R-hsa-389948 co inhibition by pd 1
- R-hsa-202424 downstream tcr signaling
- R-hsa-2029480 fcgamma receptor fcgr dependent phagocytosis
- R-hsa-9664323 fcgr3a mediated il10 synthesis
- R-hsa-2029481 fcgr activation
- R-hsa-202433 generation of second messenger molecules
Page 1 of 3
Mediation Categories (3)
Clinical-translation mediationFusion and delivery mediationImmune mediation
Relations & Evidence60
Enzyme-Mediated Modification (20)
20 records.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| CD3G | LYN | P07948 | Y | 171 | phosphorylation | Reactome_ProtMapperProtMapper | |
| CD3G | FGR | P09769 | Y | 160 | phosphorylation | Reactome_ProtMapperProtMapper | |
| CD3G | FGR | P09769 | Y | 171 | phosphorylation | Reactome_ProtMapperProtMapper | |
| CD3G | FYN | P06241 | Y | 160 | phosphorylation | Reactome_ProtMapperProtMapper | |
| CD3G | FYN | P06241 | Y | 171 | phosphorylation | Reactome_ProtMapperKEAProtMapper | KEA:17570479 |
| CD3G | YES1 | P07947 | Y | 160 | phosphorylation | Reactome_ProtMapperProtMapper | |
| CD3G | YES1 | P07947 | Y | 171 | phosphorylation | Reactome_ProtMapperProtMapper | |
| CD3G | HCK | P08631 | Y | 160 | phosphorylation | Reactome_ProtMapperProtMapper | |
| CD3G | HCK | P08631 | Y | 171 | phosphorylation | Reactome_ProtMapperProtMapper | |
| CD3G | IGF1R | P08069 | Y | 171 | phosphorylation | KEA | KEA:17570479 |
Page 2 of 2Previous
Ligand-Receptor Signaling (37)
37 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | iTALK | No | Yes | No | Yes | No |
| receptor | receptor | CellCellInteractions | No | Yes | No | Yes | No |
| receptor | receptor | EMBRACE | No | Yes | No | Yes | No |
| transmembrane | transmembrane_predicted | Phobius | No | No | No | Yes | No |
| transmembrane_phobius | transmembrane_predicted | Almen2009 | No | No | No | Yes | No |
| transmembrane_sosui | transmembrane_predicted | Almen2009 | No | No | No | Yes | No |
| transmembrane_tmhmm | transmembrane_predicted | Almen2009 | No | No | No | Yes | No |
Page 4 of 4Previous
Regulatory Interaction Network (2)
2 records.
| Source Protein Symbol | Source UniProt ID | Target Protein Symbol | Target UniProt ID | Is Directed | Is Stimulation | Is Inhibition | Database | References |
|---|---|---|---|---|---|---|---|---|
| CD3G | P09693 | CD3E | P07766 | Yes | No | No | WangNetPathHPRDHINTSignaLink3SPIKE_LCSPIKETCRcuration_SignaLink3 | SPIKE_LC:2138083HINT:35271814HINT:38657677HINT:35985289SignaLink3:23109003HINT:20890284NetPath:2138083HINT:37100770HPRD:2138083SPIKE:2138083HINT:2138083SignaLink3:15084594HINT:31461748 |
| LCK | P06239 | CD3G | P09693 | Yes | Yes | No | WangSIGNOR | SIGNOR:2470098 |
Sequence, Structure & Domains10
Sequences
Length
182
Mass
20,469
Sequence
MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLFAEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLRRN
3D Structural Models
Turn
26..28
Helix
77..79; 112..135
Beta Strand
31..33; 38..46; 50..57; 60..68; 72..76; 82..92; 97..102; 106..109
3D Structure
Electron microscopy (28); X-ray crystallography (2)
Domain & Motif Annotations
Motif
153..154; Di-leucine motif
Domain (CC)
A di-leucine motif and a tyrosine-based motif are individually sufficient to induce both endocytosis and delivery to lysosomes.
Domain (FT)
37..94; Ig-like; 149..177; ITAM
Clinical Relevance6
Disease Involvement
FDA approved drug targets
Related Diseases (5)
Biomarker
Phase 2; Phase 1/2; Phase 1
Drug Targets
FDA approved drug targets
Drugs (24)
TEBENTAFUSPANTI-CD3 MONOCLONAL ANTIBODYMUROMONAB-CD3MEDI-565SOLITOMABGLOFITAMABELRANATAMABFBT-A05FORALUMABMOSUNETUZUMABANTI-GPA33/CD3 MONOCLONAL ANTIBODY MGD007CATUMAXOMABTALQUETAMABTEPLIZUMABVISILIZUMABERTUMAXOMABAFM-11EPCORITAMABODRONEXTAMABFLOTETUZUMABIMC-GP100TECLISTAMAB-CQYVOTELIXIZUMABBLINATUMOMAB
Supporting Publications2
| PMID | Title | Abstract |
|---|---|---|
| 37922300 | Proteomic profiling of urinary extracellular vesicles differentiates breast cancer patients from healthy women. | No abstract available |
| 38731868 | The Deep Proteomics Approach Identified Extracellular Vesicular Proteins Correlated to Extracellular Matrix in Type One and Two Endometrial Cancer. | No abstract available |